GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (TSE:2160) » Definitions » Cyclically Adjusted Price-to-FCF

GNI Group (TSE:2160) Cyclically Adjusted Price-to-FCF : 2,294.51 (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is GNI Group Cyclically Adjusted Price-to-FCF?

As of today (2024-05-26), GNI Group's current share price is 円2088.00. GNI Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was 円0.91. GNI Group's Cyclically Adjusted Price-to-FCF for today is 2,294.51.

The historical rank and industry rank for GNI Group's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

TSE:2160' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 1098.71   Med: 1415.95   Max: 3162.64
Current: 2286.72

During the past years, GNI Group's highest Cyclically Adjusted Price-to-FCF was 3162.64. The lowest was 1098.71. And the median was 1415.95.

TSE:2160's Cyclically Adjusted Price-to-FCF is ranked worse than
98.08% of 104 companies
in the Biotechnology industry
Industry Median: 54.85 vs TSE:2160: 2286.72

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GNI Group's adjusted free cash flow per share data for the three months ended in Mar. 2024 was 円-12.533. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is 円0.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GNI Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GNI Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Cyclically Adjusted Price-to-FCF Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1,218.61

GNI Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1,218.61 3,384.08

Competitive Comparison of GNI Group's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GNI Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GNI Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GNI Group's Cyclically Adjusted Price-to-FCF falls into.



GNI Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GNI Group's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=2088.00/0.91
=2,294.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GNI Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GNI Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-12.533/107.2000*107.2000
=-12.533

Current CPI (Mar. 2024) = 107.2000.

GNI Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 98.000 0.000
201409 0.000 98.500 0.000
201412 0.000 97.900 0.000
201503 -10.690 97.900 -11.705
201506 -5.210 98.400 -5.676
201509 -4.581 98.500 -4.986
201512 1.355 98.100 1.481
201603 -6.772 97.900 -7.415
201606 -6.625 98.100 -7.240
201609 -1.461 98.000 -1.598
201612 -0.602 98.400 -0.656
201703 -1.603 98.100 -1.752
201706 -6.182 98.500 -6.728
201709 -10.159 98.800 -11.023
201712 1.160 99.400 1.251
201803 3.243 99.200 3.505
201806 -8.524 99.200 -9.211
201809 -3.578 99.900 -3.839
201812 3.369 99.700 3.622
201903 -1.043 99.700 -1.121
201906 3.521 99.800 3.782
201909 1.496 100.100 1.602
201912 0.146 100.500 0.156
202003 10.433 100.300 11.151
202006 3.419 99.900 3.669
202009 9.548 99.900 10.246
202012 -0.624 99.300 -0.674
202103 30.235 99.900 32.444
202106 -10.750 99.500 -11.582
202109 -13.033 100.100 -13.957
202112 -8.847 100.100 -9.475
202203 2.642 101.100 2.801
202206 -6.037 101.800 -6.357
202209 -24.171 103.100 -25.132
202212 -4.560 104.100 -4.696
202303 5.113 104.400 5.250
202306 -8.365 105.200 -8.524
202309 58.488 106.200 59.039
202312 34.200 106.800 34.328
202403 -12.533 107.200 -12.533

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GNI Group  (TSE:2160) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GNI Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GNI Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group (TSE:2160) Business Description

Industry
Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (TSE:2160) Headlines

No Headlines